Molecular Insight Pharmaceuticals, Inc. Announces Initial Public Offering.CAMBRIDGE, Mass. -- Molecular Insight Pharmaceuticals, Inc. announced today the pricing of its initial public offering of 5.0 million shares of common stock at a price of $14.00 per share. All of the shares are being sold by Molecular Insight. Molecular Insight's common stock will trade on the Nasdaq Global Market under the trading symbol Trading symbol See: Ticker symbol "MIPI MIPI Mobile Industry Processor Interface MIPI Music Industry Privacy Investigations ." RBC Capital Markets RBC Capital Markets is the corporate and investment banking division of Royal Bank of Canada ("RBC"). Broker dealers Depending on the jurisdiction, the division uses different broker dealer subsidiaries of RBC:
This offering will be made only by means of a prospectus. Copies of the final prospectus Final Prospectus A legal document stating the price of a newly issued security, the delivery date, and other facts that are important for investors. Notes: The final prospectus must be given to every investor who purchases a new issue of registered securities. related to the offering may be obtained from the offices of RBC Capital Markets Corporation, One Liberty Plaza One Liberty Plaza is a skyscraper in lower Manhattan, New York, which resides at the location of the former Singer Building (in 1968, the second tallest building to be demolished). One Liberty Plaza is currently owned and operated by Brookfield Properties. , 165 Broadway, New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , NY 10006 and Jefferies & Company, Inc., 520 Madison Ave., New York, NY 10022. A registration statement relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc these securities was declared effective by the U.S. Securities and Exchange Commission on February 1, 2007. This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction where such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. About Molecular Insight Pharmaceuticals, Inc. Molecular Insight Pharmaceuticals is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve patient healthcare by addressing significant unmet needs. The company is focused on discovering, developing and commercializing innovative and targeted radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology. Molecular Insight's lead radiotherapeutic product candidates, Azedra and Onalta, are under development for the treatment of cancer. The company's lead molecular imaging pharmaceutical product candidate, Zemiva, is under development for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. In addition, the company has a growing pipeline of product candidates resulting from application of its proprietary platform technologies to new and existing compounds. Molecular Insight Pharmaceuticals, Inc. is based in Cambridge, Massachusetts This article is about the city of Cambridge in Massachusetts. For the English university town, see Cambridge, England. For other places, see Cambridge (disambiguation). Cambridge, Massachusetts is a city in the Greater Boston area of Massachusetts, United States. . |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion